Loncar China BioPharma ETF (CHNA) ist ein börsennotiertes Unternehmen im Finanzdienstleistungen Sektor, tätig in der Asset Management Branche.
CHNA hat IPO-Datum 2018-08-15, gelistet an der NASDAQ Global Market.
The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.
